Intellia Therapeutics, Inc.
Developing curative CRISPR/Cas9 genome editing therapies for severe genetic disorders.
NTLA | NDAQ
Overview
Corporate Details
- ISIN(s):
- US45826J1051
- LEI:
- Country:
- United States of America
- Address:
- 40 ERIE STREET, 2139 CAMBRIDGE
- Website:
- https://www.intelliatx.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Intellia Therapeutics, Inc. is a clinical-stage genome editing company dedicated to developing novel, potentially curative therapeutics using CRISPR/Cas9 technology. The company's mission is to address severe and life-threatening diseases by correcting their underlying genetic causes. Intellia's pipeline is built on a full-spectrum approach, advancing both in vivo programs, where therapies are administered directly to edit genes within the body, and ex vivo programs, where cells are edited outside the body before being returned to the patient. The company focuses on developing proprietary treatments for a range of genetic disorders.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Intellia Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Intellia Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Intellia Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
